Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

As an affordability crisis grows in pricey New England, the rising cost of prescription drugs is squeezing patients, health ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access ...

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

Expanding obesity treatment access could generate $10 trillion for the country by boosting productivity, cutting healthcare ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

The Therapeutic Goods Administration (TGA) issued the warning on Thursday for products labelled with the batch number MPSD916, which has been confirmed as ingenuine by Ozempic manufacturer Novo ...